Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease

Tanta University

Status

Enrolling

Conditions

Metabolic Dysfunction-Associated Fatty Liver Disease

Thyroid Dysfunction

Treatments

Device: Fibroscan

Study type

Observational

Funder types

Other

Identifiers

NCT06739330

36264PR929/11/24

Details and patient eligibility

About

This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.

Full description

One of the most common causes of chronic liver diseases worldwide is metabolic dysfunction-associated fatty liver disease (MAFLD), which affects about 30% of adults. Thyroid hormones are critical in maintaining metabolic homeostasis throughout life and are intimately linked to the liver.

Dysfunctions of the thyroid gland have been implicated as one of the most important risk factors of MAFLD due to its important role in the hepatic synthesis of fatty acid and cholesterol. Maintaining liver metabolism requires thyroid function to be normal, while thyroid disorders may lead to liver disease progression.

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age ≥ 18 years.
Both sexes.
Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).

Exclusion criteria

History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
Viral hepatitis.
Pregnant women.